JP2020522487A - ストレス障害のホルモンカスケードを調節する組成物および方法 - Google Patents
ストレス障害のホルモンカスケードを調節する組成物および方法 Download PDFInfo
- Publication number
- JP2020522487A JP2020522487A JP2019566098A JP2019566098A JP2020522487A JP 2020522487 A JP2020522487 A JP 2020522487A JP 2019566098 A JP2019566098 A JP 2019566098A JP 2019566098 A JP2019566098 A JP 2019566098A JP 2020522487 A JP2020522487 A JP 2020522487A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- isoflavone
- natural
- combination
- lipoic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 92
- 238000000034 method Methods 0.000 title abstract description 28
- 230000003054 hormonal effect Effects 0.000 title description 22
- 208000013200 Stress disease Diseases 0.000 title description 10
- 235000008696 isoflavones Nutrition 0.000 claims abstract description 66
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims abstract description 65
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims abstract description 51
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract description 45
- 150000002515 isoflavone derivatives Chemical class 0.000 claims abstract description 32
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 29
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 27
- 239000002243 precursor Substances 0.000 claims abstract description 24
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 36
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 claims description 22
- 229960003638 dopamine Drugs 0.000 claims description 20
- 235000015724 Trifolium pratense Nutrition 0.000 claims description 19
- 235000013526 red clover Nutrition 0.000 claims description 18
- WUADCCWRTIWANL-UHFFFAOYSA-N biochanin A Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O WUADCCWRTIWANL-UHFFFAOYSA-N 0.000 claims description 16
- 241000196324 Embryophyta Species 0.000 claims description 13
- 244000111261 Mucuna pruriens Species 0.000 claims description 11
- 235000006161 Mucuna pruriens Nutrition 0.000 claims description 11
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 5
- 159000000000 sodium salts Chemical class 0.000 claims description 4
- 239000003954 decarboxylase inhibitor Substances 0.000 claims description 2
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 claims description 2
- 239000005445 natural material Substances 0.000 claims 2
- 229940123736 Decarboxylase inhibitor Drugs 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 230000035882 stress Effects 0.000 abstract description 40
- 150000001875 compounds Chemical class 0.000 abstract description 24
- 239000003270 steroid hormone Substances 0.000 abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 19
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract description 19
- 230000037326 chronic stress Effects 0.000 abstract description 17
- 208000035475 disorder Diseases 0.000 abstract description 13
- 238000011260 co-administration Methods 0.000 abstract description 9
- 208000001640 Fibromyalgia Diseases 0.000 abstract description 7
- 201000009273 Endometriosis Diseases 0.000 abstract description 4
- 238000010586 diagram Methods 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 description 51
- 239000005556 hormone Substances 0.000 description 51
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 25
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 24
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 20
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 18
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 17
- 229930182833 estradiol Natural products 0.000 description 17
- 229960005309 estradiol Drugs 0.000 description 17
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 230000003827 upregulation Effects 0.000 description 14
- 230000003828 downregulation Effects 0.000 description 13
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 208000020016 psychiatric disease Diseases 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 229960003604 testosterone Drugs 0.000 description 10
- 230000003110 anti-inflammatory effect Effects 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 9
- 235000007240 daidzein Nutrition 0.000 description 9
- 235000006539 genistein Nutrition 0.000 description 9
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 9
- 229940045109 genistein Drugs 0.000 description 9
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 102000006378 Catechol O-methyltransferase Human genes 0.000 description 8
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 8
- 239000000470 constituent Substances 0.000 description 8
- 229960000890 hydrocortisone Drugs 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 7
- -1 adiol Chemical compound 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000007170 pathology Effects 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 201000009032 substance abuse Diseases 0.000 description 7
- 208000011117 substance-related disease Diseases 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 6
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 6
- 235000010469 Glycine max Nutrition 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- 241000122904 Mucuna Species 0.000 description 6
- 230000001594 aberrant effect Effects 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 6
- 229960002478 aldosterone Drugs 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 150000003431 steroids Chemical class 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000003340 mental effect Effects 0.000 description 5
- 235000020746 red clover extract Nutrition 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 208000017667 Chronic Disease Diseases 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- 244000068988 Glycine max Species 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000003938 response to stress Effects 0.000 description 4
- 231100000736 substance abuse Toxicity 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 3
- QADHLRWLCPCEKT-UHFFFAOYSA-N Androstenediol Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)O)C4C3CC=C21 QADHLRWLCPCEKT-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 3
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 3
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 240000002913 Trifolium pratense Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 3
- 229960004544 cortisone Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000007124 immune defense Effects 0.000 description 3
- 229960004502 levodopa Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 201000011461 pre-eclampsia Diseases 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 230000000472 traumatic effect Effects 0.000 description 3
- UUAYQRPSGVHQFO-FJXCUIBHSA-N (8R,9S,10R,13R,14S)-10,13-dimethyl-1,2,3,6,7,8,9,11,12,14,16,17-dodecahydrocyclopenta[a]phenanthrene-15,15,16-triol Chemical compound C1CC2=CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C(O)(O)C(O)C[C@@]1(C)CC2 UUAYQRPSGVHQFO-FJXCUIBHSA-N 0.000 description 2
- CBMYJHIOYJEBSB-YSZCXEEOSA-N 5alpha-androstane-3beta,17beta-diol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 CBMYJHIOYJEBSB-YSZCXEEOSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- WDPFQABQVGJEBZ-MAKOZQESSA-N Bothermon Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 WDPFQABQVGJEBZ-MAKOZQESSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 201000002832 Lewy body dementia Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 244000046146 Pueraria lobata Species 0.000 description 2
- 235000010575 Pueraria lobata Nutrition 0.000 description 2
- 244000042314 Vigna unguiculata Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- QADHLRWLCPCEKT-LOVVWNRFSA-N androst-5-ene-3beta,17beta-diol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC=C21 QADHLRWLCPCEKT-LOVVWNRFSA-N 0.000 description 2
- 229950009148 androstenediol Drugs 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006999 cognitive decline Effects 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 208000002296 eclampsia Diseases 0.000 description 2
- 150000002159 estradiols Chemical class 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000004090 neuroprotective agent Substances 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- IBAFAEHLNXQMQA-OFLQVFCSSA-N (8r,9s,10s,13s,14s)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15-dodecahydro-1h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound C1C(O)CC[C@]2(C)[C@H]3CC[C@](C)(C(=CC4)O)[C@@H]4[C@@H]3CCC21 IBAFAEHLNXQMQA-OFLQVFCSSA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- DILDHNKDVHLEQB-XSSYPUMDSA-N 2-hydroxy-17beta-estradiol Chemical compound OC1=C(O)C=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 DILDHNKDVHLEQB-XSSYPUMDSA-N 0.000 description 1
- 208000037853 Abnormal uterine bleeding Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000007333 Brain Concussion Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000030523 Catechol oxidase Human genes 0.000 description 1
- 108010031396 Catechol oxidase Proteins 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010013496 Disturbance in attention Diseases 0.000 description 1
- 206010049119 Emotional distress Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000000509 Estrogen Receptor beta Human genes 0.000 description 1
- 108010041356 Estrogen Receptor beta Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 101000878457 Macrocallista nimbosa FMRFamide Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 201000009916 Postpartum depression Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000208422 Rhododendron Species 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 241000219873 Vicia Species 0.000 description 1
- 240000006677 Vicia faba Species 0.000 description 1
- 235000010749 Vicia faba Nutrition 0.000 description 1
- 235000002098 Vicia faba var. major Nutrition 0.000 description 1
- 241000219977 Vigna Species 0.000 description 1
- 235000010726 Vigna sinensis Nutrition 0.000 description 1
- 235000010722 Vigna unguiculata Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000013061 administrable dose form Substances 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960004205 carbidopa Drugs 0.000 description 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 244000013123 dwarf bean Species 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001814 effect on stress Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000021331 green beans Nutrition 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- JDWYRSDDJVCWPB-LURJTMIESA-N leucodopachrome Chemical compound OC1=C(O)C=C2N[C@H](C(=O)O)CC2=C1 JDWYRSDDJVCWPB-LURJTMIESA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960001652 norethindrone acetate Drugs 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002898 organic sulfur compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940124811 psychiatric drug Drugs 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000009211 stress pathway Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
定義:
本明細書で使用される「治療有効量」という用語は、特定された疾患もしくは病態を治療、改善もしくは予防するのに、またはヒトステロイドホルモンカスケードに異常を来たす慢性ストレス障害に罹患しているヒトに投与したとき、検出可能な治療効果、予防効果もしくは阻害効果がみられるのに、十分な化合物の濃度または用量を指す。
上記のように、イソフラボン構成成分は、好ましくは天然由来であり、その天然のグリコシド型の糖から分離しているアグリコン型であり、のちに記載するイソフラボン構成成分のプロファイルが得られる発酵または任意の形態の抽出によって得られるものであり得る。USPグレードのアカツメクサ抽出物が好ましい植物性供給源であるが、特に限定されないが、ダイズ(Glycine max L)、サヤインゲン(Phaseolus vulgaris L.)、アルファスプラウト(Meicago satica L.)、ヤエナリスプラウト(Vigna radiata L.)、ササゲ(Vigna unguiculata L.)、クズ根(Puerarya lobata L.)ならびに特にアカツメクサ花およびアカツメクサスプラウト(Trifolrum pratense L.)またはソラマメを含めた多数の他の植物種がイソフラボンの供給源となり得る。
αリポ酸はストレス下にある個体のコレステロールを増大させることが知られており、このコレステロールは、次いでDHEA、アジオールおよびテストステロンに変換される。アルファリポ酸はこれまでに、それがエネルギー代謝および活性酸素種(ROS)による細胞内損傷からの保護に果たす役割について研究されてきた。これらの化合物のin vivo濃度のアップレギュレーションまたは維持によりヒトステロイドホルモンカスケードの正常化が促進される。アルファリポ酸は、上の実施例1に記載されている選択したイソフラボン濃度で相乗効果を示す。図4を参照すると、アルファリポ酸は、オクタン酸から誘導される有機硫黄化合物であり、通常、真核細胞中に存在し、好気性代謝に必要なものである。アルファリポ酸には、ジスルフィド結合によって結合した2個の硫黄原子(C6、C8)が含まれており、いずれの硫黄原子も、より高い酸化状態で存在することができる。C6炭素原子はキラルであり、アルファリポ酸の2つの鏡像異性体は(R)−(+)および(L)(−)として存在する。本発明の目的には、(R)−(+)鏡像異性体が高度に濃縮されたアルファリポ酸構成成分が好ましい。特に好ましい製剤では、(R)(+)濃縮組成物のナトリウム塩が、選択した製剤パラメータによる生物学的利用能および溶解度を増大させる。好ましいリポ酸濃度は、(R)(+)鏡像異性体が全体で少なくとも80%、好ましくは少なくとも90%であり、不溶性ポリマーが比較的少ない(2.0%未満)。粗組成物には、R−リポ酸ナトリウム塩の9〜10%のナトリウム、微量の炭酸塩および可溶性ポリマーが含まれている。in vivo試験から、本明細書に記載される好ましいR−リポ酸の製剤が生物学的利用能および溶解度を増大させることがわかっている。好ましい組成物は、実質的に有機溶媒を含まず、比旋光度[アルファ]D20=+60〜+85であり、融点が240℃〜250℃であり、約210℃で分解が始まる。粒子径は40メッシュ未満である。製剤加工の過程で、50℃未満の熱を維持することにより、構成成分中の好ましい(R)(+)鏡像異性体の比が保持される。
図5を参照すると、レボドパ(L−DOPA)(L−3,4ジヒドロキシフェニルアラニン−(S)−アミノ)はこれまで、神経細胞の神経伝達物質ドーパミンの合成不全に対処するのに投与されてきた。しかし、ドーパミンとは対照的に、Lドーパは血液脳(脳)関門を通過して神経細胞内に入ることができ、そこでカルボキシル化されてドーパミンとなる。Lドーパは、自己酸化またはチロシネアーゼ(tyrosinease)(ポリフェノールオキシダーゼ)との反応により、メラニンを生じるロイコドーパクロムおよびドーパクロムに酸化され得る。
上記の3種類の活性成分の共投与により、ステロイドが好ましいカスケードに回復する。共投与は、本発明の3種類の成分を一定の時間内に少なくとも2種類の成分、好ましくは全3種類の成分の間の相乗効果が得られる濃度で同時に投与することと定義される。これには、アルドステロンおよびコルチゾンの減少ならびにエストラジオール、2−メトキシエストラジオール(2ME)、テストステロンおよび強力な免疫調節性アジオール(例えば、アンドロステンジオール)の増加が含まれる。これと同時に、エストラジオールおよびカテコールアミン(例えば、ドーパミン、エピネフリンおよびノルエピネフリン)を分解する酵素であるCOMT(カテコール−O−メチルトランスフェラーゼ)が減少する。
粘膜下筋腫または子宮癌などの器質性病理の不在下での子宮内膜症、続発性無月経および異常子宮出血はホルモンの不均衡に起因するものである。これらの病態は疼痛および子宮出血を特徴とする。現在の治療法としては、完全に効果的なものはないが、女性ホルモン、酢酸ノルエチンドロンおよびプロゲスチンの投与が挙げられる。本発明の方法は、必要とする患者の子宮内膜症の治療に本明細書に明記される組成物を投与することを含む。
線維筋痛症は、疲労、睡眠、記憶力および気分の問題を伴い広範囲に及ぶ筋骨格痛を特徴とする障害である。研究者らは、線維筋痛症が、脳が疼痛シグナルを処理する経路に影響を及ぼすことによって痛覚を増幅すると考えている。身体的外傷、外科手術、感染症または大きな心理的ストレスの後に症状が始まることがある。他の場合には、引き金となる事象が一切みられずに症状が徐々に蓄積する。本発明の方法は、必要とする患者の線維筋痛症の治療に本明細書に明記される組成物を投与することを含む。
PTSDなどの重度の精神疾患および精神障害の身体的基礎については十分に理解されていないが、両病態とも急性もしくは軽度の外傷性脳損傷または反復脳振盪が原因であることがある。PTSDは通常、対象、精神外傷をもたらす出来事および社会との関わりの間の相互作用であるとされており、この相互作用が身体的ストレス要素を精神的ストレス要素に起因する慢性病態として持続させる。PTSDは免疫障害および炎症性障害に大きな影響を及ぼすことがこれまでに観察されており、免疫系機能不全を伴うPTSDおよびSMD関連ストレスの発症と、炎症要素を含む慢性疾患との間には強い相関がみられる。PTSD、SMDともにその共存症が認められているが、統一された治療は存在しない。したがって、本発明の方法は、必要とする患者に治療有効量の本発明の組成物を投与することを含む。
ステロイドホルモンカスケードの崩壊は、いくつかの異なる心血管系の共存症を引き起こす。慢性ストレスが、特に限定されないが、アテローム性動脈硬化症、高血圧、持続性高血圧、血管障害および血管剛性の増大を含めた急性および慢性疾患の一因となることがこれまでに観察されている。本発明の方法は、慢性の心理的ストレスに起因する心血管障害に治療的介入が必要な患者に本明細書に記載される組成物を投与することを含む。
慢性ストレスは物質乱用、離脱症状の原因でも結果でもあり、持続的なステロイドホルモンカスケードの歪みが物質乱用による長期的作用である可能性が考えられる。本発明の方法は、物質乱用者、離脱症状のある者または長期的な物質乱用による害を抑える漸減戦略を用いている者に治療有効量の本明細書に記載される組成物を送達することを含む。本発明の方法論では、本発明の組成物の直接的な治療投与を、依存性物質を自己投与する強迫行為を引き起こす慢性ストレスの軽減、依存性物質の離脱症状もしくは依存性物質使用の漸減によるストレスの軽減、または短期的および長期的物質乱用に起因するストレス誘発性共存症の直接的軽減にともに適用することができる。
包括的用語である認知症は、様々な生理学的特徴を有する複数の障害、例えばアルツハイマー病、レビー小体型認知症および長期認知低下を特徴とするその他の形態の病理を包含する。調査研究により、心理的ストレスなどの慢性ストレスは、それが中年期のものであっても、認知症と見なされる可能性のあるいずれかの障害を伴う精神機能低下の一因となり得ることが明らかにされている。本発明の組成物の投与は、認知低下を引き起こすストレス誘発性の生理学的事象の軽減ならびに罹患者による精神機能低下に起因するストレスに伴う共存症の軽減の両方に役立つ。
Claims (18)
- 前記イソフラボンの組合せがさらに、R1=HとR2=CH3およびR1=OHとR2=CH3ならびにその組合せを有するイソフラボン化合物からなる、請求項1に記載の組成物。
- 前記イソフラボンの組合せがさらに、R1=HとR2=HおよびR1=HとR2=OHならびにその組合せを有するイソフラボンからなる、請求項1に記載の組成物。
- 前記イソフラボンの組合せがさらに、アカツメクサの天然の非イソフラボン構成成分からなる、請求項1に記載の組成物。
- 前記天然の物質がさらに、ハッショウマメ(Mucuna pruriens)に天然に存在する非ドーパミン構成成分からなる、請求項1に記載の組成物。
- 前記ドーパミン前駆体が、表1に記載される属からなる群より選択される植物種およびその組合せに存在するものである、請求項1に記載の組成物。
- 前記アルファリポ酸、前記天然のドーパミン前駆体および前記イソフラボンの組合せがそれぞれ、少なくとも2mgの有効成分の前記天然のドーパミン前駆体の濃度で単一剤形として組み合わさっている、請求項1に記載の組成物。
- 前記アルファリポ酸、前記天然のドーパミン前駆体および前記イソフラボンの組合せがそれぞれ、前記天然のドーパミン前駆体の含有量が約2mg〜6mgの有効成分5mg〜30mgの単一剤形として組み合わさっている、請求項1に記載の組成物。
- 前記アルファリポ酸および前記天然のドーパミン前駆体がそれぞれ、前記イソフラボンの組合せの含有量が100〜500mgの単一剤形として組み合わさっている、請求項1に記載の組成物。
- 前記アルファリポ酸、前記天然のドーパミン前駆体および前記イソフラボンの組合せがそれぞれ、ビオカニンAとホルモノネチンとの組合せからなる総イソフラボン含有量が少なくとも240ミリグラムの単一剤形として組み合わさっている、請求項1に記載の組成物。
- 前記アルファリポ酸、前記天然のドーパミン前駆体、および前記イソフラボンの組合せがそれぞれ、総イソフラボン含有量が少なくとも300ミリグラムの単一剤形として組み合わさっている、請求項1に記載の組成物。
- アカツメクサ由来の天然の植物組織からさらになる、請求項1に記載の組成物。
- 前記ドーパミン前駆体が、実質的にL型のドーパミンからなり、実質的にD型のドーパミンを含まない、請求項1に記載の組成物。
- 末梢神経系デカルボキシラーゼ阻害剤をさらに含む、請求項1に記載の組成物。
- 組成物B6をさらに含む、請求項1に記載の組成物。
- 前記アルファリポ酸の用量が、前記(R)(+)鏡像異性体が少なくとも85%に濃縮されたものである、請求項1に記載の組成物。
- 前記アルファリポ酸がそのナトリウム塩である、請求項16に記載の組成物。
- 請求項1〜17のいずれかに記載の組成物の薬物としての使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762512713P | 2017-05-30 | 2017-05-30 | |
US62/512,713 | 2017-05-30 | ||
PCT/US2018/035227 WO2018222781A2 (en) | 2017-05-30 | 2018-05-30 | Compositions and methods to regulate hormonal cascades in stress disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2020522487A true JP2020522487A (ja) | 2020-07-30 |
Family
ID=64455682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019566098A Pending JP2020522487A (ja) | 2017-05-30 | 2018-05-30 | ストレス障害のホルモンカスケードを調節する組成物および方法 |
Country Status (11)
Country | Link |
---|---|
US (3) | US10588890B2 (ja) |
EP (1) | EP3634398A4 (ja) |
JP (1) | JP2020522487A (ja) |
KR (1) | KR20200015534A (ja) |
CN (1) | CN110996987A (ja) |
AU (1) | AU2018275543A1 (ja) |
BR (1) | BR112019024845A2 (ja) |
CA (1) | CA3065135A1 (ja) |
EA (1) | EA201992566A1 (ja) |
IL (1) | IL270899A (ja) |
WO (1) | WO2018222781A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022094634A1 (en) * | 2020-10-27 | 2022-05-05 | Sunstar Joint Stock Company | Preparation made from herbs for enhancing memory and treating dementia syndrome |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019094596A1 (en) | 2017-11-09 | 2019-05-16 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
BR112021008602A2 (pt) | 2018-11-26 | 2021-08-03 | The Procter & Gamble Company | preparação farmacêutica sólida contendo ácido lipoico e uso da mesma |
IT202000020839A1 (it) * | 2020-09-02 | 2022-03-02 | Crystal Hemp Sa | "nuova composizione per il trattamento delle malattie neurodegenerative" |
WO2022250488A1 (ko) * | 2021-05-28 | 2022-12-01 | 연세대학교 산학협력단 | 난소내막종의 예방 또는 치료용 조성물 |
CN113244218B (zh) * | 2021-07-01 | 2022-05-31 | 暨南大学 | 芒柄花黄素在制备治疗或/和预防抑郁症药物中的应用 |
WO2024112847A1 (en) * | 2022-11-23 | 2024-05-30 | Iowa State University Research Foundation, Inc. | Methods of making, protecting, and delivering stable prebiotic compositions |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001213775A (ja) * | 2000-02-03 | 2001-08-07 | Pola Chem Ind Inc | ストレス軽減剤及びそれを含有してなる皮膚外用剤 |
US20020016478A1 (en) * | 2000-07-20 | 2002-02-07 | Linnea Sa | Dry extract which is rich in isoflavones in the form of aglycones and process for preparing the same |
JP2003535134A (ja) * | 2000-06-08 | 2003-11-25 | フィアトリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 痴呆治療剤 |
JP2004250372A (ja) * | 2003-02-20 | 2004-09-09 | Fancl Corp | 皮膚老化防止・改善剤及び/又は肌荒れ防止・改善剤キット |
JP2006507288A (ja) * | 2002-10-30 | 2006-03-02 | フュトリックス・アクチェンゲゼルシャフト | 神経学的な疾患の処置におけるハッショウマメ種の粉末およびそのエキスを含有する医薬組成物、並びにその使用法 |
US20060257502A1 (en) * | 2005-05-11 | 2006-11-16 | Jiankang Liu | A combination of mitochondrial nutrients for relieving stress, preventing and improving stress-related disorders |
EP1854486A2 (de) * | 2006-03-14 | 2007-11-14 | Wilfried P. Bieger | Verwendung von Neurotransmitter-Derivaten zur Herstellung von Mitteln zur Behandlung von neuroendokrinen gesundheitlichen Störungen |
US20110064712A1 (en) * | 2009-09-16 | 2011-03-17 | Daniel Moses Amato | Dietary Supplement Compositions and Methods of Making and Using the Same |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070059378A1 (en) * | 2001-02-02 | 2007-03-15 | Metagenics, Inc. | Medical composition for balancing bodily processes |
ITMI20031534A1 (it) * | 2003-07-25 | 2005-01-26 | Marfarma S R L Ora Marfarma Holdin G S P A | Composizioni per il trattamento di ansia e disturbi correlati |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
WO2006105440A2 (en) * | 2005-03-30 | 2006-10-05 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
US20070292536A1 (en) * | 2006-06-16 | 2007-12-20 | Gottfried Kellermann | Composition and method for treating patients with high neurotransmitter levels |
CA2659511A1 (en) | 2006-08-02 | 2008-02-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anticonvulsive pharmaceutical compositions |
EP2182952A4 (en) * | 2007-07-23 | 2010-09-08 | Synosia Therapeutics | TREATMENT OF POST-TRAUMATIC STRESS DISORDER |
DE102007034957B4 (de) * | 2007-07-26 | 2016-11-03 | Monika Hönscher-Sickert | Kosmetisches Verfahren zur Beeinflussung der Haut |
IT1392101B1 (it) * | 2008-12-12 | 2012-02-09 | Zuccari Societa A Responsabilita Limitata In Breve Zuccari S R L | Composizione comprendente isoflavoni |
US20130034537A1 (en) * | 2010-12-08 | 2013-02-07 | Gocan Anca-Gabriela | Simultaneous co-treatment of physical and mental symptoms related to severe mental disorders by a specially fermented soy formulation (fsww08) |
-
2018
- 2018-05-30 EA EA201992566A patent/EA201992566A1/ru unknown
- 2018-05-30 WO PCT/US2018/035227 patent/WO2018222781A2/en active Application Filing
- 2018-05-30 BR BR112019024845A patent/BR112019024845A2/pt not_active Application Discontinuation
- 2018-05-30 KR KR1020197036395A patent/KR20200015534A/ko not_active Application Discontinuation
- 2018-05-30 AU AU2018275543A patent/AU2018275543A1/en not_active Abandoned
- 2018-05-30 JP JP2019566098A patent/JP2020522487A/ja active Pending
- 2018-05-30 EP EP18809687.9A patent/EP3634398A4/en not_active Withdrawn
- 2018-05-30 CA CA3065135A patent/CA3065135A1/en not_active Abandoned
- 2018-05-30 US US15/993,576 patent/US10588890B2/en active Active
- 2018-05-30 CN CN201880035488.8A patent/CN110996987A/zh active Pending
-
2019
- 2019-11-25 IL IL270899A patent/IL270899A/en unknown
-
2020
- 2020-03-03 US US16/807,659 patent/US11337955B2/en active Active
-
2022
- 2022-05-23 US US17/750,716 patent/US20230022324A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001213775A (ja) * | 2000-02-03 | 2001-08-07 | Pola Chem Ind Inc | ストレス軽減剤及びそれを含有してなる皮膚外用剤 |
JP2003535134A (ja) * | 2000-06-08 | 2003-11-25 | フィアトリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 痴呆治療剤 |
US20020016478A1 (en) * | 2000-07-20 | 2002-02-07 | Linnea Sa | Dry extract which is rich in isoflavones in the form of aglycones and process for preparing the same |
JP2006507288A (ja) * | 2002-10-30 | 2006-03-02 | フュトリックス・アクチェンゲゼルシャフト | 神経学的な疾患の処置におけるハッショウマメ種の粉末およびそのエキスを含有する医薬組成物、並びにその使用法 |
JP2004250372A (ja) * | 2003-02-20 | 2004-09-09 | Fancl Corp | 皮膚老化防止・改善剤及び/又は肌荒れ防止・改善剤キット |
US20060257502A1 (en) * | 2005-05-11 | 2006-11-16 | Jiankang Liu | A combination of mitochondrial nutrients for relieving stress, preventing and improving stress-related disorders |
EP1854486A2 (de) * | 2006-03-14 | 2007-11-14 | Wilfried P. Bieger | Verwendung von Neurotransmitter-Derivaten zur Herstellung von Mitteln zur Behandlung von neuroendokrinen gesundheitlichen Störungen |
US20110064712A1 (en) * | 2009-09-16 | 2011-03-17 | Daniel Moses Amato | Dietary Supplement Compositions and Methods of Making and Using the Same |
Non-Patent Citations (5)
Title |
---|
H. P. YADAV ET AL.: "The Development of Treatment for Parkinson’s Disease", ADVANCES IN PARKINSON’S DISEASE, vol. 4, JPN7022000880, 2015, pages 59 - 78, ISSN: 0004904236 * |
K. NATARAJAN ET AL.: "REVIEW ON "MUCUNA" - THE WONDER PLANT", INT. J. PHARM. SCI. REV. RES., vol. 17 (1), JPN7022000879, 2012, pages 86 - 93, ISSN: 0004904237 * |
N. TABASSUM ET AL.: "Natural Cognitive Enhancers", J. OF PHARMACY RES., vol. 5 (1), JPN7022000882, 2012, pages 153 - 160, ISSN: 0004904234 * |
P. C. JOSHI: "A REVIEW ON NATURAL MEMORY ENHANCERS (NOOTROPICS)", UNIQUE J. OF ENGINEERING AND ADVANCED SCI., vol. 1 (1), JPN7022000881, 2013, pages 8 - 18, ISSN: 0004904235 * |
S. KASTURE ET AL.: "Mucuna pruriens seeds in treatment of Parkinson’s disease: pharmacological review", ORIENT PHARM EXP MED, vol. 13 (3), JPN7022000878, 2013, pages 165 - 174, ISSN: 0004904238 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022094634A1 (en) * | 2020-10-27 | 2022-05-05 | Sunstar Joint Stock Company | Preparation made from herbs for enhancing memory and treating dementia syndrome |
Also Published As
Publication number | Publication date |
---|---|
AU2018275543A1 (en) | 2020-01-16 |
KR20200015534A (ko) | 2020-02-12 |
US20200197363A1 (en) | 2020-06-25 |
US20230022324A1 (en) | 2023-01-26 |
US11337955B2 (en) | 2022-05-24 |
WO2018222781A2 (en) | 2018-12-06 |
CN110996987A (zh) | 2020-04-10 |
BR112019024845A2 (pt) | 2020-06-09 |
US10588890B2 (en) | 2020-03-17 |
CA3065135A1 (en) | 2019-12-06 |
EP3634398A2 (en) | 2020-04-15 |
WO2018222781A3 (en) | 2020-04-09 |
EP3634398A4 (en) | 2021-06-02 |
EA201992566A1 (ru) | 2020-04-10 |
IL270899A (en) | 2020-01-30 |
US20180344687A1 (en) | 2018-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11337955B2 (en) | Compositions and methods to regulate hormonal cascades in stress disorders | |
JP5345778B2 (ja) | 肥満、肥満に関連する障害、および他の障害の治療/管理におけるプレグナン配糖体の使用 | |
WO2005107779A2 (en) | Weight loss composition and method of inducing weight loss | |
JP2005513107A (ja) | (−)−ヒドロキシクエン酸、クロム、およびギムネマ酸を含有する組成物、および健常体重を促進する方法と関連する健康因子を改善する方法 | |
PL209905B1 (pl) | Preparat do leczenia otyłości i związanego z nią syndromu metabolicznego | |
TR201802570T4 (tr) | Obezi̇teni̇n tedavi̇si̇ne ve önlenmesi̇ne yöneli̇k formülasyonlar | |
US8435963B2 (en) | Weight loss compositions and uses thereof | |
US20150157672A1 (en) | Kits and methods for sustained weight loss | |
EP2705762B1 (en) | Biologically active dietary supplement for normalizing the androgen level in men and the overall condition and reducing obesity | |
CN105233288A (zh) | 一种治疗或预防肥胖型高血压的药物组合物及其用途 | |
US10610556B2 (en) | Compositions for regulation and control of appetite | |
WO2009093353A1 (ja) | 医薬組成物 | |
Frączek et al. | Effectiveness of slimming aid products as perceived by a group of young women reducing their body mass | |
WO2014128639A1 (en) | Composition for the treatment of metabolic disorders | |
WO2005007152A1 (en) | Treating cachexia and excessive catabolism with (-)-hydroxycitric acid | |
WO2020163519A1 (en) | Compositions and methods for the treatment of constipation and other ailments of the gastrointestinal system | |
CA3026043A1 (en) | Therapeutic compositions and methods | |
WO2011159850A2 (en) | Lip cosmetic formulations | |
JP2009196996A (ja) | 医薬組成物 | |
Badmaev et al. | Coleus forskohlii: Fat-Fighting and More | |
Greenway et al. | 25 Herbal and Alternative Approaches |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210528 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220222 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220301 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220530 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220728 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20221025 |